FDA Updates Drug Manufacturing Situation in Puerto Rico
By

By
The US Food and Drug Administration (FDA) has updated the agency’s efforts in supporting pharmaceutical manufacturing in Puerto Rico following Hurricanes Irma and Maria. This follows an earlier update from…

Allergan Posts 3Q Loss of $4 Billion
By

By
Allergan has reported a third-quarter operating loss of $4.02 billion due to impairment charges for its top-selling drug, Restasis (cyclosporine ophthalmic emulsion), following a setback in patent litigation as well…

EU-US Mutual Recognition of Inspections Enters Operational Phase
By

By
A mutual recognition agreement for manufacturing inspections between the European Union (EU) and the US has entered the operational phase. The pact, which updates an agreement from 1998, enables both…

The Medicines Company Announces Restructuring
By

By
The Medicines Company, a Parsippany, New Jersey-based pharmaceutical company, has announced a restructuring program under which the company plans to divest its Infectious Disease Business (ID) and reduce its employee…

CureVac Breaks Ground on New Mfg Facility for RNA Therapeutics
By

By
CureVac, a Tübingen, Germany-headquartered clinical-stage biopharmaceutical company focused on mRNA (messenger ribonucleic acid)-based drug development, has broken ground for an industrial-scale production facility at its headquarters. The GMP-compliant production facility…

Roquette Opens Regional HQ in Singapore
By

By
Roquette, a La Madeleine, France-based provider of excipients and food ingredients, has opened new offices and an innovation center in Singapore. The facilities include a research laboratory, customer technical services…

Catalent in Biomanufacturing Pact
By

By
Catalent Pharma Solutions has signed a multi-year agreement with Grid Therapeutics, a Durham, North Carolina-headquartered biotechnology company focused on oncology, for the development and manufacture of Grid’s lead therapeutic candidate…

FDA Issues Draft Guidance on GDUFA II User-Fee Structure
By

By
The US Food and Drug Administration (FDA) has issued draft guidance, Assessing User Fees Under the Generic Drug User Fee Amendments of 2017, to outline the new user-fee structure under…

Novartis to Acquire Advanced Accelerator Applications for $3.9 Billion
By

By
As part of a move to strengthen its oncology portfolio, Novartis has signed a memorandum of understanding with Advanced Accelerator Applications (AAA), a Saint-Genis-Pouilly, France-headquartered radiopharmaceutical company, under which Novartis…

Mustang Bio Invests in CAR-T Therapy Manufacturing Facility
By

By
Mustang Bio, a New York-headquartered clinical-stage biopharmaceutical company and a subsidiary of the biopharmaceutical company, Fortress Biotech, has entered into a lease agreement with the UMass Medicine Science Park in…